nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—melanoma	0.423	1	CtDrD
Gefitinib—EGFR—melanoma	0.116	0.616	CbGaD
Gefitinib—EGFR—Docetaxel—melanoma	0.0532	0.239	CbGbCtD
Gefitinib—ORM1—Vemurafenib—melanoma	0.042	0.188	CbGbCtD
Gefitinib—ALB—melanoma	0.037	0.196	CbGaD
Gefitinib—ABCB1—melanoma	0.0354	0.187	CbGaD
Gefitinib—ABCG2—Vemurafenib—melanoma	0.0256	0.115	CbGbCtD
Gefitinib—CYP1A1—Dacarbazine—melanoma	0.0181	0.0813	CbGbCtD
Gefitinib—ALB—Vemurafenib—melanoma	0.0177	0.0793	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—melanoma	0.017	0.0764	CbGbCtD
Gefitinib—CYP3A4—Temozolomide—melanoma	0.0101	0.0453	CbGbCtD
Gefitinib—ABCG2—Docetaxel—melanoma	0.00879	0.0395	CbGbCtD
Gefitinib—CYP2D6—Vemurafenib—melanoma	0.0087	0.0391	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—melanoma	0.00614	0.0275	CbGbCtD
Gefitinib—CYP3A4—Vemurafenib—melanoma	0.00553	0.0248	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—melanoma	0.00487	0.0219	CbGbCtD
Gefitinib—ABCB1—Docetaxel—melanoma	0.00317	0.0142	CbGbCtD
Gefitinib—CYP3A4—Docetaxel—melanoma	0.0019	0.00852	CbGbCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—melanoma	0.00115	1	CbGdCrCtD
Gefitinib—ERBB3—hair follicle—melanoma	0.00104	0.0522	CbGeAlD
Gefitinib—MKNK2—hair follicle—melanoma	0.000987	0.0496	CbGeAlD
Gefitinib—IRAK1—hair follicle—melanoma	0.000987	0.0496	CbGeAlD
Gefitinib—MKNK1—hair follicle—melanoma	0.000974	0.049	CbGeAlD
Gefitinib—SBK1—eye—melanoma	0.000972	0.0489	CbGeAlD
Gefitinib—SBK1—retina—melanoma	0.000963	0.0484	CbGeAlD
Gefitinib—SBK1—head—melanoma	0.000552	0.0278	CbGeAlD
Gefitinib—CSNK1E—retina—melanoma	0.000532	0.0268	CbGeAlD
Gefitinib—MKNK2—eye—melanoma	0.000493	0.0248	CbGeAlD
Gefitinib—Lapatinib—ERBB4—melanoma	0.00049	0.118	CrCbGaD
Gefitinib—MKNK2—retina—melanoma	0.000488	0.0246	CbGeAlD
Gefitinib—MKNK1—eye—melanoma	0.000486	0.0245	CbGeAlD
Gefitinib—MKNK1—retina—melanoma	0.000482	0.0242	CbGeAlD
Gefitinib—CSNK1E—skin of body—melanoma	0.000467	0.0235	CbGeAlD
Gefitinib—CYP1A1—skin epidermis—melanoma	0.000464	0.0233	CbGeAlD
Gefitinib—ERBB3—skin of body—melanoma	0.000451	0.0227	CbGeAlD
Gefitinib—EGFR—mammalian vulva—melanoma	0.000443	0.0223	CbGeAlD
Gefitinib—EPHA6—head—melanoma	0.000431	0.0217	CbGeAlD
Gefitinib—CSNK1E—mammalian vulva—melanoma	0.000426	0.0214	CbGeAlD
Gefitinib—IRAK4—mammalian vulva—melanoma	0.000419	0.0211	CbGeAlD
Gefitinib—MAP3K19—head—melanoma	0.000392	0.0197	CbGeAlD
Gefitinib—MKNK2—mammalian vulva—melanoma	0.000391	0.0197	CbGeAlD
Gefitinib—IRAK1—mammalian vulva—melanoma	0.000391	0.0197	CbGeAlD
Gefitinib—SBK1—lymph node—melanoma	0.000386	0.0194	CbGeAlD
Gefitinib—MKNK1—mammalian vulva—melanoma	0.000386	0.0194	CbGeAlD
Gefitinib—Ulcer—Bleomycin—melanoma	0.000362	0.00679	CcSEcCtD
Gefitinib—Lapatinib—ERBB2—melanoma	0.000362	0.0872	CrCbGaD
Gefitinib—Afatinib—ERBB4—melanoma	0.000347	0.0837	CrCbGaD
Gefitinib—Bosutinib—PKMYT1—melanoma	0.000338	0.0815	CrCbGaD
Gefitinib—Ulcer—Dactinomycin—melanoma	0.000338	0.00633	CcSEcCtD
Gefitinib—CHEK2—lymph node—melanoma	0.000337	0.0169	CbGeAlD
Gefitinib—Cystitis noninfective—Bleomycin—melanoma	0.000335	0.00627	CcSEcCtD
Gefitinib—Cystitis—Bleomycin—melanoma	0.000331	0.0062	CcSEcCtD
Gefitinib—Drug interaction—Carmustine—melanoma	0.000323	0.00604	CcSEcCtD
Gefitinib—Weight decreased—Vemurafenib—melanoma	0.000321	0.00601	CcSEcCtD
Gefitinib—Febrile neutropenia—Docetaxel—melanoma	0.00032	0.00599	CcSEcCtD
Gefitinib—STK10—mammalian vulva—melanoma	0.000318	0.016	CbGeAlD
Gefitinib—Infestation—Vemurafenib—melanoma	0.000317	0.00593	CcSEcCtD
Gefitinib—Infestation NOS—Vemurafenib—melanoma	0.000317	0.00593	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.000314	0.00588	CcSEcCtD
Gefitinib—Eruption—Docetaxel—melanoma	0.000313	0.00585	CcSEcCtD
Gefitinib—Bladder pain—Bleomycin—melanoma	0.00031	0.0058	CcSEcCtD
Gefitinib—CSNK1E—head—melanoma	0.000305	0.0153	CbGeAlD
Gefitinib—IRAK4—head—melanoma	0.0003	0.0151	CbGeAlD
Gefitinib—Nail disorder—Docetaxel—melanoma	0.000297	0.00555	CcSEcCtD
Gefitinib—Respiratory failure—Temozolomide—melanoma	0.000294	0.00551	CcSEcCtD
Gefitinib—ERBB3—head—melanoma	0.000294	0.0148	CbGeAlD
Gefitinib—Mouth ulceration—Dactinomycin—melanoma	0.000289	0.00541	CcSEcCtD
Gefitinib—Bosutinib—SYK—melanoma	0.000288	0.0693	CrCbGaD
Gefitinib—MAP2K5—mammalian vulva—melanoma	0.000284	0.0143	CbGeAlD
Gefitinib—Oedema peripheral—Vemurafenib—melanoma	0.00028	0.00524	CcSEcCtD
Gefitinib—MKNK2—head—melanoma	0.00028	0.0141	CbGeAlD
Gefitinib—MKNK1—head—melanoma	0.000276	0.0139	CbGeAlD
Gefitinib—Interstitial lung disease—Docetaxel—melanoma	0.000272	0.00509	CcSEcCtD
Gefitinib—Erythema multiforme—Vemurafenib—melanoma	0.000269	0.00503	CcSEcCtD
Gefitinib—Dry eye—Temozolomide—melanoma	0.000267	0.005	CcSEcCtD
Gefitinib—Eye disorder—Vemurafenib—melanoma	0.000266	0.00497	CcSEcCtD
Gefitinib—Cardiac disorder—Vemurafenib—melanoma	0.000264	0.00494	CcSEcCtD
Gefitinib—Hepatic failure—Dactinomycin—melanoma	0.000258	0.00484	CcSEcCtD
Gefitinib—Angiopathy—Vemurafenib—melanoma	0.000258	0.00483	CcSEcCtD
Gefitinib—Afatinib—ERBB2—melanoma	0.000256	0.0618	CrCbGaD
Gefitinib—Mediastinal disorder—Vemurafenib—melanoma	0.000256	0.0048	CcSEcCtD
Gefitinib—Pleural effusion—Docetaxel—melanoma	0.000251	0.0047	CcSEcCtD
Gefitinib—Alopecia—Vemurafenib—melanoma	0.000251	0.0047	CcSEcCtD
Gefitinib—Thrombophlebitis—Carmustine—melanoma	0.000251	0.0047	CcSEcCtD
Gefitinib—Malnutrition—Vemurafenib—melanoma	0.000247	0.00463	CcSEcCtD
Gefitinib—Thrombophlebitis—Temozolomide—melanoma	0.000243	0.00454	CcSEcCtD
Gefitinib—Eye pain—Carmustine—melanoma	0.000241	0.00451	CcSEcCtD
Gefitinib—Bosutinib—CDK2—melanoma	0.000234	0.0565	CrCbGaD
Gefitinib—Bosutinib—EPHA2—melanoma	0.000234	0.0565	CrCbGaD
Gefitinib—Hepatic failure—Temozolomide—melanoma	0.000234	0.00437	CcSEcCtD
Gefitinib—Eye pain—Temozolomide—melanoma	0.000233	0.00435	CcSEcCtD
Gefitinib—STK10—head—melanoma	0.000227	0.0114	CbGeAlD
Gefitinib—Dermatitis exfoliative—Temozolomide—melanoma	0.000222	0.00417	CcSEcCtD
Gefitinib—EGFR—lymph node—melanoma	0.000222	0.0112	CbGeAlD
Gefitinib—Bosutinib—MAP2K2—melanoma	0.000218	0.0525	CrCbGaD
Gefitinib—Cough—Vemurafenib—melanoma	0.000216	0.00404	CcSEcCtD
Gefitinib—CSNK1E—lymph node—melanoma	0.000213	0.0107	CbGeAlD
Gefitinib—IRAK4—lymph node—melanoma	0.00021	0.0106	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000209	0.00392	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.000209	0.00391	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000209	0.00391	CcSEcCtD
Gefitinib—Drug interaction—Docetaxel—melanoma	0.000207	0.00388	CcSEcCtD
Gefitinib—ERBB3—lymph node—melanoma	0.000206	0.0104	CbGeAlD
Gefitinib—MAP2K5—head—melanoma	0.000203	0.0102	CbGeAlD
Gefitinib—Infection—Vemurafenib—melanoma	0.000201	0.00376	CcSEcCtD
Gefitinib—Nervous system disorder—Vemurafenib—melanoma	0.000198	0.00371	CcSEcCtD
Gefitinib—Hypokalaemia—Carmustine—melanoma	0.000198	0.0037	CcSEcCtD
Gefitinib—Skin disorder—Vemurafenib—melanoma	0.000196	0.00367	CcSEcCtD
Gefitinib—Respiratory failure—Docetaxel—melanoma	0.000196	0.00367	CcSEcCtD
Gefitinib—MKNK2—lymph node—melanoma	0.000196	0.00985	CbGeAlD
Gefitinib—IRAK1—lymph node—melanoma	0.000196	0.00985	CbGeAlD
Gefitinib—Dehydration—Temozolomide—melanoma	0.000195	0.00366	CcSEcCtD
Gefitinib—Weight decreased—Bleomycin—melanoma	0.000195	0.00364	CcSEcCtD
Gefitinib—MKNK1—lymph node—melanoma	0.000193	0.00972	CbGeAlD
Gefitinib—Pneumonia—Bleomycin—melanoma	0.000193	0.00361	CcSEcCtD
Gefitinib—Dry skin—Temozolomide—melanoma	0.000192	0.0036	CcSEcCtD
Gefitinib—Hypokalaemia—Temozolomide—melanoma	0.000191	0.00358	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000189	0.00354	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000189	0.00354	CcSEcCtD
Gefitinib—Hypotension—Vemurafenib—melanoma	0.000189	0.00353	CcSEcCtD
Gefitinib—Stomatitis—Bleomycin—melanoma	0.000187	0.0035	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000185	0.00347	CcSEcCtD
Gefitinib—Haematuria—Bleomycin—melanoma	0.000183	0.00342	CcSEcCtD
Gefitinib—Pneumonia—Dactinomycin—melanoma	0.00018	0.00337	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000177	0.00332	CcSEcCtD
Gefitinib—Decreased appetite—Vemurafenib—melanoma	0.000175	0.00329	CcSEcCtD
Gefitinib—Stomatitis—Dactinomycin—melanoma	0.000174	0.00326	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000174	0.00326	CcSEcCtD
Gefitinib—Fatigue—Vemurafenib—melanoma	0.000174	0.00326	CcSEcCtD
Gefitinib—Haemoglobin—Bleomycin—melanoma	0.000173	0.00324	CcSEcCtD
Gefitinib—Constipation—Vemurafenib—melanoma	0.000173	0.00323	CcSEcCtD
Gefitinib—Haemorrhage—Bleomycin—melanoma	0.000172	0.00322	CcSEcCtD
Gefitinib—Lapatinib—EGFR—melanoma	0.000171	0.0412	CrCbGaD
Gefitinib—Pneumonia—Carmustine—melanoma	0.000168	0.00315	CcSEcCtD
Gefitinib—Bosutinib—MAP2K1—melanoma	0.000165	0.0398	CrCbGaD
Gefitinib—Bosutinib—PTK2B—melanoma	0.000165	0.0398	CrCbGaD
Gefitinib—Weight decreased—Temozolomide—melanoma	0.000164	0.00307	CcSEcCtD
Gefitinib—Stomatitis—Carmustine—melanoma	0.000163	0.00306	CcSEcCtD
Gefitinib—Pneumonia—Temozolomide—melanoma	0.000163	0.00305	CcSEcCtD
Gefitinib—Infestation—Temozolomide—melanoma	0.000162	0.00303	CcSEcCtD
Gefitinib—Infestation NOS—Temozolomide—melanoma	0.000162	0.00303	CcSEcCtD
Gefitinib—Thrombophlebitis—Docetaxel—melanoma	0.000161	0.00302	CcSEcCtD
Gefitinib—ABCB1—blood vessel—melanoma	0.000161	0.00811	CbGeAlD
Gefitinib—Hepatitis—Dactinomycin—melanoma	0.000161	0.00301	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00016	0.003	CcSEcCtD
Gefitinib—Body temperature increased—Vemurafenib—melanoma	0.00016	0.00299	CcSEcCtD
Gefitinib—STK10—lymph node—melanoma	0.000159	0.00801	CbGeAlD
Gefitinib—Stomatitis—Temozolomide—melanoma	0.000158	0.00295	CcSEcCtD
Gefitinib—Hepatic failure—Docetaxel—melanoma	0.000155	0.00291	CcSEcCtD
Gefitinib—Hepatobiliary disease—Temozolomide—melanoma	0.000153	0.00287	CcSEcCtD
Gefitinib—Alopecia—Bleomycin—melanoma	0.000152	0.00285	CcSEcCtD
Gefitinib—Erythema multiforme—Dactinomycin—melanoma	0.000152	0.00284	CcSEcCtD
Gefitinib—Bosutinib—ERBB4—melanoma	0.000151	0.0364	CrCbGaD
Gefitinib—Haemoglobin—Carmustine—melanoma	0.000151	0.00283	CcSEcCtD
Gefitinib—Haemorrhage—Carmustine—melanoma	0.00015	0.00281	CcSEcCtD
Gefitinib—Hypersensitivity—Vemurafenib—melanoma	0.000149	0.00279	CcSEcCtD
Gefitinib—Oedema peripheral—Carmustine—melanoma	0.000148	0.00277	CcSEcCtD
Gefitinib—Atrial fibrillation—Docetaxel—melanoma	0.000147	0.00276	CcSEcCtD
Gefitinib—Dermatitis bullous—Docetaxel—melanoma	0.000146	0.00274	CcSEcCtD
Gefitinib—Haemoglobin—Temozolomide—melanoma	0.000146	0.00273	CcSEcCtD
Gefitinib—Hepatitis—Temozolomide—melanoma	0.000145	0.00272	CcSEcCtD
Gefitinib—Haemorrhage—Temozolomide—melanoma	0.000145	0.00272	CcSEcCtD
Gefitinib—Asthenia—Vemurafenib—melanoma	0.000145	0.00271	CcSEcCtD
Gefitinib—CYP1A1—skin of body—melanoma	0.000144	0.00723	CbGeAlD
Gefitinib—Urinary tract disorder—Temozolomide—melanoma	0.000143	0.00269	CcSEcCtD
Gefitinib—Oedema peripheral—Temozolomide—melanoma	0.000143	0.00268	CcSEcCtD
Gefitinib—Pruritus—Vemurafenib—melanoma	0.000143	0.00267	CcSEcCtD
Gefitinib—Urethral disorder—Temozolomide—melanoma	0.000142	0.00267	CcSEcCtD
Gefitinib—MAP2K5—lymph node—melanoma	0.000142	0.00715	CbGeAlD
Gefitinib—Alopecia—Dactinomycin—melanoma	0.000142	0.00266	CcSEcCtD
Gefitinib—Eye disorder—Carmustine—melanoma	0.00014	0.00263	CcSEcCtD
Gefitinib—Anaemia—Bleomycin—melanoma	0.000139	0.00259	CcSEcCtD
Gefitinib—Diarrhoea—Vemurafenib—melanoma	0.000138	0.00259	CcSEcCtD
Gefitinib—ABCG2—mammalian vulva—melanoma	0.000138	0.00694	CbGeAlD
Gefitinib—Erythema multiforme—Temozolomide—melanoma	0.000137	0.00257	CcSEcCtD
Gefitinib—Eye disorder—Temozolomide—melanoma	0.000136	0.00254	CcSEcCtD
Gefitinib—Malaise—Bleomycin—melanoma	0.000135	0.00253	CcSEcCtD
Gefitinib—Cardiac disorder—Temozolomide—melanoma	0.000135	0.00252	CcSEcCtD
Gefitinib—Arrhythmia—Carmustine—melanoma	0.000134	0.00251	CcSEcCtD
Gefitinib—Alopecia—Carmustine—melanoma	0.000133	0.00249	CcSEcCtD
Gefitinib—Angiopathy—Temozolomide—melanoma	0.000132	0.00247	CcSEcCtD
Gefitinib—CYP1A1—mammalian vulva—melanoma	0.000131	0.00659	CbGeAlD
Gefitinib—Mediastinal disorder—Temozolomide—melanoma	0.000131	0.00245	CcSEcCtD
Gefitinib—Malnutrition—Carmustine—melanoma	0.000131	0.00245	CcSEcCtD
Gefitinib—Cough—Bleomycin—melanoma	0.000131	0.00245	CcSEcCtD
Gefitinib—Dehydration—Docetaxel—melanoma	0.00013	0.00243	CcSEcCtD
Gefitinib—Anaemia—Dactinomycin—melanoma	0.000129	0.00242	CcSEcCtD
Gefitinib—Vomiting—Vemurafenib—melanoma	0.000128	0.0024	CcSEcCtD
Gefitinib—Alopecia—Temozolomide—melanoma	0.000128	0.0024	CcSEcCtD
Gefitinib—Dry skin—Docetaxel—melanoma	0.000128	0.0024	CcSEcCtD
Gefitinib—Rash—Vemurafenib—melanoma	0.000127	0.00238	CcSEcCtD
Gefitinib—Dermatitis—Vemurafenib—melanoma	0.000127	0.00238	CcSEcCtD
Gefitinib—Malnutrition—Temozolomide—melanoma	0.000126	0.00237	CcSEcCtD
Gefitinib—Malaise—Dactinomycin—melanoma	0.000126	0.00236	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000126	0.00235	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000126	0.00235	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000123	0.00231	CcSEcCtD
Gefitinib—Infection—Bleomycin—melanoma	0.000122	0.00228	CcSEcCtD
Gefitinib—Afatinib—EGFR—melanoma	0.000121	0.0292	CrCbGaD
Gefitinib—Anaemia—Carmustine—melanoma	0.000121	0.00226	CcSEcCtD
Gefitinib—Nausea—Vemurafenib—melanoma	0.00012	0.00225	CcSEcCtD
Gefitinib—Thrombocytopenia—Bleomycin—melanoma	0.00012	0.00224	CcSEcCtD
Gefitinib—Anaemia—Temozolomide—melanoma	0.000117	0.00219	CcSEcCtD
Gefitinib—Anorexia—Bleomycin—melanoma	0.000117	0.00218	CcSEcCtD
Gefitinib—Angioedema—Temozolomide—melanoma	0.000116	0.00216	CcSEcCtD
Gefitinib—ORM1—lymph node—melanoma	0.000115	0.00581	CbGeAlD
Gefitinib—Hypotension—Bleomycin—melanoma	0.000114	0.00214	CcSEcCtD
Gefitinib—Malaise—Temozolomide—melanoma	0.000114	0.00213	CcSEcCtD
Gefitinib—Infection—Dactinomycin—melanoma	0.000113	0.00212	CcSEcCtD
Gefitinib—Thrombocytopenia—Dactinomycin—melanoma	0.000112	0.00209	CcSEcCtD
Gefitinib—Cough—Temozolomide—melanoma	0.00011	0.00207	CcSEcCtD
Gefitinib—Weight decreased—Docetaxel—melanoma	0.000109	0.00204	CcSEcCtD
Gefitinib—Dyspnoea—Bleomycin—melanoma	0.000109	0.00204	CcSEcCtD
Gefitinib—Anorexia—Dactinomycin—melanoma	0.000109	0.00204	CcSEcCtD
Gefitinib—Pneumonia—Docetaxel—melanoma	0.000108	0.00203	CcSEcCtD
Gefitinib—Infestation NOS—Docetaxel—melanoma	0.000108	0.00201	CcSEcCtD
Gefitinib—Infestation—Docetaxel—melanoma	0.000108	0.00201	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000107	0.002	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000107	0.002	CcSEcCtD
Gefitinib—Decreased appetite—Bleomycin—melanoma	0.000106	0.00199	CcSEcCtD
Gefitinib—Infection—Carmustine—melanoma	0.000106	0.00199	CcSEcCtD
Gefitinib—Dry mouth—Temozolomide—melanoma	0.000105	0.00197	CcSEcCtD
Gefitinib—Stomatitis—Docetaxel—melanoma	0.000105	0.00196	CcSEcCtD
Gefitinib—Pain—Bleomycin—melanoma	0.000105	0.00196	CcSEcCtD
Gefitinib—Conjunctivitis—Docetaxel—melanoma	0.000105	0.00196	CcSEcCtD
Gefitinib—Thrombocytopenia—Carmustine—melanoma	0.000105	0.00196	CcSEcCtD
Gefitinib—Infection—Temozolomide—melanoma	0.000103	0.00192	CcSEcCtD
Gefitinib—Anorexia—Carmustine—melanoma	0.000102	0.00191	CcSEcCtD
Gefitinib—Hepatobiliary disease—Docetaxel—melanoma	0.000102	0.00191	CcSEcCtD
Gefitinib—Epistaxis—Docetaxel—melanoma	0.000101	0.0019	CcSEcCtD
Gefitinib—ALB—lymph node—melanoma	0.000101	0.00509	CbGeAlD
Gefitinib—Nervous system disorder—Temozolomide—melanoma	0.000101	0.00189	CcSEcCtD
Gefitinib—Thrombocytopenia—Temozolomide—melanoma	0.000101	0.00189	CcSEcCtD
Gefitinib—Skin disorder—Temozolomide—melanoma	0.0001	0.00188	CcSEcCtD
Gefitinib—Hypotension—Carmustine—melanoma	9.98e-05	0.00187	CcSEcCtD
Gefitinib—Decreased appetite—Dactinomycin—melanoma	9.92e-05	0.00186	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—melanoma	9.84e-05	0.00184	CcSEcCtD
Gefitinib—Anorexia—Temozolomide—melanoma	9.84e-05	0.00184	CcSEcCtD
Gefitinib—Pain—Dactinomycin—melanoma	9.76e-05	0.00183	CcSEcCtD
Gefitinib—Urticaria—Bleomycin—melanoma	9.72e-05	0.00182	CcSEcCtD
Gefitinib—Haemoglobin—Docetaxel—melanoma	9.71e-05	0.00182	CcSEcCtD
Gefitinib—Body temperature increased—Bleomycin—melanoma	9.67e-05	0.00181	CcSEcCtD
Gefitinib—Hepatitis—Docetaxel—melanoma	9.66e-05	0.00181	CcSEcCtD
Gefitinib—Haemorrhage—Docetaxel—melanoma	9.66e-05	0.00181	CcSEcCtD
Gefitinib—Urinary tract disorder—Docetaxel—melanoma	9.54e-05	0.00179	CcSEcCtD
Gefitinib—Dyspnoea—Carmustine—melanoma	9.52e-05	0.00178	CcSEcCtD
Gefitinib—Oedema peripheral—Docetaxel—melanoma	9.51e-05	0.00178	CcSEcCtD
Gefitinib—Urethral disorder—Docetaxel—melanoma	9.47e-05	0.00177	CcSEcCtD
Gefitinib—CYP1A1—head—melanoma	9.38e-05	0.00472	CbGeAlD
Gefitinib—Gastrointestinal pain—Dactinomycin—melanoma	9.33e-05	0.00175	CcSEcCtD
Gefitinib—Decreased appetite—Carmustine—melanoma	9.28e-05	0.00174	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Carmustine—melanoma	9.22e-05	0.00173	CcSEcCtD
Gefitinib—Dyspnoea—Temozolomide—melanoma	9.2e-05	0.00172	CcSEcCtD
Gefitinib—Erythema multiforme—Docetaxel—melanoma	9.13e-05	0.00171	CcSEcCtD
Gefitinib—Constipation—Carmustine—melanoma	9.13e-05	0.00171	CcSEcCtD
Gefitinib—Pain—Carmustine—melanoma	9.13e-05	0.00171	CcSEcCtD
Gefitinib—Erlotinib—CYP1B1—melanoma	9.07e-05	0.0219	CrCbGaD
Gefitinib—Eye disorder—Docetaxel—melanoma	9.03e-05	0.00169	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—melanoma	9.02e-05	0.00169	CcSEcCtD
Gefitinib—Abdominal pain—Dactinomycin—melanoma	9.02e-05	0.00169	CcSEcCtD
Gefitinib—Hypersensitivity—Bleomycin—melanoma	9.01e-05	0.00169	CcSEcCtD
Gefitinib—Decreased appetite—Temozolomide—melanoma	8.97e-05	0.00168	CcSEcCtD
Gefitinib—Cardiac disorder—Docetaxel—melanoma	8.96e-05	0.00168	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Temozolomide—melanoma	8.91e-05	0.00167	CcSEcCtD
Gefitinib—Fatigue—Temozolomide—melanoma	8.9e-05	0.00167	CcSEcCtD
Gefitinib—Constipation—Temozolomide—melanoma	8.82e-05	0.00165	CcSEcCtD
Gefitinib—Pain—Temozolomide—melanoma	8.82e-05	0.00165	CcSEcCtD
Gefitinib—Asthenia—Bleomycin—melanoma	8.78e-05	0.00164	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—melanoma	8.76e-05	0.00164	CcSEcCtD
Gefitinib—Gastrointestinal pain—Carmustine—melanoma	8.73e-05	0.00163	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—melanoma	8.7e-05	0.00163	CcSEcCtD
Gefitinib—Pruritus—Bleomycin—melanoma	8.65e-05	0.00162	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—melanoma	8.63e-05	0.00162	CcSEcCtD
Gefitinib—Erlotinib—EGFR—melanoma	8.56e-05	0.0206	CrCbGaD
Gefitinib—Alopecia—Docetaxel—melanoma	8.53e-05	0.0016	CcSEcCtD
Gefitinib—ABCB1—retina—melanoma	8.5e-05	0.00428	CbGeAlD
Gefitinib—Abdominal pain—Carmustine—melanoma	8.44e-05	0.00158	CcSEcCtD
Gefitinib—Body temperature increased—Carmustine—melanoma	8.44e-05	0.00158	CcSEcCtD
Gefitinib—Gastrointestinal pain—Temozolomide—melanoma	8.44e-05	0.00158	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—melanoma	8.41e-05	0.00157	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—melanoma	8.4e-05	0.00157	CcSEcCtD
Gefitinib—Urticaria—Temozolomide—melanoma	8.2e-05	0.00153	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—melanoma	8.18e-05	0.00153	CcSEcCtD
Gefitinib—Abdominal pain—Temozolomide—melanoma	8.16e-05	0.00153	CcSEcCtD
Gefitinib—Body temperature increased—Temozolomide—melanoma	8.16e-05	0.00153	CcSEcCtD
Gefitinib—Vandetanib—KDR—melanoma	7.89e-05	0.019	CrCbGaD
Gefitinib—Hypersensitivity—Carmustine—melanoma	7.87e-05	0.00147	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—melanoma	7.81e-05	0.00146	CcSEcCtD
Gefitinib—Vomiting—Bleomycin—melanoma	7.78e-05	0.00146	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—melanoma	7.77e-05	0.00146	CcSEcCtD
Gefitinib—Rash—Bleomycin—melanoma	7.71e-05	0.00144	CcSEcCtD
Gefitinib—Dermatitis—Bleomycin—melanoma	7.71e-05	0.00144	CcSEcCtD
Gefitinib—Asthenia—Carmustine—melanoma	7.66e-05	0.00143	CcSEcCtD
Gefitinib—Hypersensitivity—Temozolomide—melanoma	7.6e-05	0.00142	CcSEcCtD
Gefitinib—Asthenia—Temozolomide—melanoma	7.4e-05	0.00139	CcSEcCtD
Gefitinib—Cough—Docetaxel—melanoma	7.34e-05	0.00137	CcSEcCtD
Gefitinib—Diarrhoea—Carmustine—melanoma	7.31e-05	0.00137	CcSEcCtD
Gefitinib—Pruritus—Temozolomide—melanoma	7.3e-05	0.00137	CcSEcCtD
Gefitinib—Nausea—Bleomycin—melanoma	7.27e-05	0.00136	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—melanoma	7.25e-05	0.00136	CcSEcCtD
Gefitinib—Rash—Dactinomycin—melanoma	7.19e-05	0.00135	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	7.11e-05	0.00133	CcSEcCtD
Gefitinib—Diarrhoea—Temozolomide—melanoma	7.06e-05	0.00132	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—melanoma	7e-05	0.00131	CcSEcCtD
Gefitinib—ABCG2—lymph node—melanoma	6.92e-05	0.00348	CbGeAlD
Gefitinib—Infection—Docetaxel—melanoma	6.82e-05	0.00128	CcSEcCtD
Gefitinib—ABCB1—mammalian vulva—melanoma	6.81e-05	0.00342	CbGeAlD
Gefitinib—Vomiting—Carmustine—melanoma	6.79e-05	0.00127	CcSEcCtD
Gefitinib—Nausea—Dactinomycin—melanoma	6.78e-05	0.00127	CcSEcCtD
Gefitinib—CYP2D6—head—melanoma	6.77e-05	0.00341	CbGeAlD
Gefitinib—Shock—Docetaxel—melanoma	6.75e-05	0.00126	CcSEcCtD
Gefitinib—Rash—Carmustine—melanoma	6.73e-05	0.00126	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—melanoma	6.73e-05	0.00126	CcSEcCtD
Gefitinib—Dermatitis—Carmustine—melanoma	6.73e-05	0.00126	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—melanoma	6.72e-05	0.00126	CcSEcCtD
Gefitinib—Vandetanib—VEGFA—melanoma	6.69e-05	0.0161	CrCbGaD
Gefitinib—Skin disorder—Docetaxel—melanoma	6.66e-05	0.00125	CcSEcCtD
Gefitinib—CYP1A1—lymph node—melanoma	6.57e-05	0.0033	CbGeAlD
Gefitinib—Vomiting—Temozolomide—melanoma	6.56e-05	0.00123	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—melanoma	6.54e-05	0.00122	CcSEcCtD
Gefitinib—Rash—Temozolomide—melanoma	6.51e-05	0.00122	CcSEcCtD
Gefitinib—Dermatitis—Temozolomide—melanoma	6.5e-05	0.00122	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—melanoma	6.41e-05	0.0012	CcSEcCtD
Gefitinib—Nausea—Carmustine—melanoma	6.34e-05	0.00119	CcSEcCtD
Gefitinib—Nausea—Temozolomide—melanoma	6.13e-05	0.00115	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—melanoma	6.12e-05	0.00115	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—melanoma	5.96e-05	0.00112	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—melanoma	5.92e-05	0.00111	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—melanoma	5.92e-05	0.00111	CcSEcCtD
Gefitinib—Constipation—Docetaxel—melanoma	5.87e-05	0.0011	CcSEcCtD
Gefitinib—Pain—Docetaxel—melanoma	5.87e-05	0.0011	CcSEcCtD
Gefitinib—Vandetanib—EGFR—melanoma	5.64e-05	0.0136	CrCbGaD
Gefitinib—Gastrointestinal pain—Docetaxel—melanoma	5.61e-05	0.00105	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—melanoma	5.42e-05	0.00102	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—melanoma	5.42e-05	0.00102	CcSEcCtD
Gefitinib—Bosutinib—EGFR—melanoma	5.28e-05	0.0127	CrCbGaD
Gefitinib—Lapatinib—ABCB1—melanoma	5.2e-05	0.0125	CrCbGaD
Gefitinib—Hypersensitivity—Docetaxel—melanoma	5.06e-05	0.000947	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—melanoma	4.92e-05	0.000922	CcSEcCtD
Gefitinib—ABCB1—head—melanoma	4.87e-05	0.00245	CbGeAlD
Gefitinib—Pruritus—Docetaxel—melanoma	4.85e-05	0.000909	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—melanoma	4.69e-05	0.000879	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—melanoma	4.36e-05	0.000817	CcSEcCtD
Gefitinib—Rash—Docetaxel—melanoma	4.33e-05	0.00081	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—melanoma	4.32e-05	0.000809	CcSEcCtD
Gefitinib—Nausea—Docetaxel—melanoma	4.08e-05	0.000763	CcSEcCtD
Gefitinib—Afatinib—ABCB1—melanoma	3.69e-05	0.00889	CrCbGaD
Gefitinib—ABCB1—lymph node—melanoma	3.41e-05	0.00172	CbGeAlD
Gefitinib—Erlotinib—ALB—melanoma	2.73e-05	0.00658	CrCbGaD
Gefitinib—Erlotinib—ABCB1—melanoma	2.6e-05	0.00628	CrCbGaD
Gefitinib—Vandetanib—ALB—melanoma	1.8e-05	0.00433	CrCbGaD
Gefitinib—Bosutinib—ABCB1—melanoma	1.6e-05	0.00387	CrCbGaD
Gefitinib—EGFR—Immune System—CDKN1A—melanoma	1.08e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC5A5—melanoma	1.08e-06	1.25e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—melanoma	1.08e-06	1.25e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—melanoma	1.08e-06	1.25e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.08e-06	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—melanoma	1.08e-06	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—melanoma	1.08e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PRKCA—melanoma	1.08e-06	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NFKB1—melanoma	1.07e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—melanoma	1.07e-06	1.24e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP1B1—melanoma	1.07e-06	1.24e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK3—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ERCC2—melanoma	1.07e-06	1.23e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—melanoma	1.06e-06	1.22e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAPK1—melanoma	1.06e-06	1.22e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—melanoma	1.06e-06	1.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CD80—melanoma	1.06e-06	1.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APC—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CG—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNAQ—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD44—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1A—melanoma	1.05e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNAQ—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD44—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EGF—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NFKB1—melanoma	1.04e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLA2G6—melanoma	1.03e-06	1.19e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CD—melanoma	1.03e-06	1.19e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—melanoma	1.03e-06	1.19e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—melanoma	1.03e-06	1.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—melanoma	1.03e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.02e-06	1.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—melanoma	1.02e-06	1.18e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—melanoma	1.02e-06	1.18e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAPK1—melanoma	1.02e-06	1.17e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—melanoma	1.02e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PRKCA—melanoma	1.02e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.01e-06	1.17e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK3—melanoma	1.01e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP1B1—melanoma	1.01e-06	1.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK3—melanoma	1.01e-06	1.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ERCC2—melanoma	1.01e-06	1.16e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—melanoma	1.01e-06	1.16e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—melanoma	1.01e-06	1.16e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP1B1—melanoma	1e-06	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—melanoma	9.98e-07	1.15e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—melanoma	9.98e-07	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—melanoma	9.96e-07	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—melanoma	9.9e-07	1.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	9.69e-07	1.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—melanoma	9.65e-07	1.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—melanoma	9.65e-07	1.11e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MAPK1—melanoma	9.64e-07	1.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—melanoma	9.63e-07	1.11e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—melanoma	9.62e-07	1.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAPK1—melanoma	9.6e-07	1.11e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—melanoma	9.48e-07	1.09e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—melanoma	9.42e-07	1.09e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—melanoma	9.33e-07	1.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAP2K1—melanoma	9.32e-07	1.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—melanoma	9.31e-07	1.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—melanoma	9.3e-07	1.07e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—VCAN—melanoma	9.29e-07	1.07e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PRKCA—melanoma	9.27e-07	1.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—melanoma	9.26e-07	1.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK3—melanoma	9.22e-07	1.06e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—melanoma	9.19e-07	1.06e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—melanoma	9.17e-07	1.06e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—melanoma	9.1e-07	1.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—melanoma	9.07e-07	1.05e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—melanoma	9.04e-07	1.04e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—melanoma	9.01e-07	1.04e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—melanoma	8.93e-07	1.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK3—melanoma	8.91e-07	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—melanoma	8.91e-07	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—melanoma	8.89e-07	1.02e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—melanoma	8.87e-07	1.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF2—melanoma	8.87e-07	1.02e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—melanoma	8.84e-07	1.02e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.83e-07	1.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAPK1—melanoma	8.77e-07	1.01e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—melanoma	8.67e-07	9.99e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—melanoma	8.55e-07	9.86e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK3—melanoma	8.51e-07	9.81e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—melanoma	8.48e-07	9.78e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAPK1—melanoma	8.48e-07	9.78e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—melanoma	8.48e-07	9.78e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—melanoma	8.43e-07	9.72e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—melanoma	8.36e-07	9.64e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.35e-07	9.63e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—melanoma	8.33e-07	9.6e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PRKCA—melanoma	8.32e-07	9.59e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—melanoma	8.31e-07	9.58e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—melanoma	8.3e-07	9.57e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—melanoma	8.28e-07	9.55e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—melanoma	8.28e-07	9.54e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—melanoma	8.25e-07	9.51e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—melanoma	8.24e-07	9.5e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—melanoma	8.18e-07	9.43e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—melanoma	8.18e-07	9.43e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—melanoma	8.13e-07	9.38e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—melanoma	8.12e-07	9.36e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PRKCA—melanoma	8.12e-07	9.36e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAPK1—melanoma	8.1e-07	9.34e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—melanoma	8.09e-07	9.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—melanoma	8.07e-07	9.31e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—melanoma	8.05e-07	9.28e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—melanoma	8.01e-07	9.24e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—melanoma	7.96e-07	9.18e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP17A1—melanoma	7.84e-07	9.04e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—melanoma	7.83e-07	9.02e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—melanoma	7.79e-07	8.98e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—melanoma	7.76e-07	8.94e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—melanoma	7.74e-07	8.92e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—melanoma	7.71e-07	8.89e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—melanoma	7.68e-07	8.86e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PRKCA—melanoma	7.65e-07	8.82e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—melanoma	7.65e-07	8.82e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.61e-07	8.78e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—melanoma	7.61e-07	8.78e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—melanoma	7.59e-07	8.75e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PRKCA—melanoma	7.58e-07	8.74e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—melanoma	7.58e-07	8.73e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—melanoma	7.52e-07	8.67e-06	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—melanoma	7.49e-07	8.64e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—melanoma	7.43e-07	8.56e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—melanoma	7.41e-07	8.55e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—melanoma	7.41e-07	8.54e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNA11—melanoma	7.41e-07	8.54e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—melanoma	7.38e-07	8.5e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—melanoma	7.36e-07	8.48e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—melanoma	7.31e-07	8.43e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—melanoma	7.26e-07	8.37e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FASN—melanoma	7.25e-07	8.35e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—melanoma	7.23e-07	8.33e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—melanoma	7.22e-07	8.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—melanoma	7.16e-07	8.25e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC5A5—melanoma	7.13e-07	8.22e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—melanoma	7.12e-07	8.21e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—melanoma	7.04e-07	8.12e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—melanoma	7.03e-07	8.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—melanoma	7.02e-07	8.09e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—melanoma	7.01e-07	8.08e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—melanoma	7e-07	8.07e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—melanoma	6.99e-07	8.06e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—melanoma	6.98e-07	8.04e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKB1—melanoma	6.94e-07	8e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—melanoma	6.91e-07	7.97e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNAQ—melanoma	6.88e-07	7.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD44—melanoma	6.88e-07	7.94e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.83e-07	7.88e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—melanoma	6.83e-07	7.88e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—melanoma	6.81e-07	7.85e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—melanoma	6.81e-07	7.85e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—melanoma	6.74e-07	7.77e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1B1—melanoma	6.6e-07	7.61e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—melanoma	6.52e-07	7.51e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—melanoma	6.52e-07	7.51e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—melanoma	6.5e-07	7.5e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—melanoma	6.46e-07	7.44e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—melanoma	6.4e-07	7.38e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—melanoma	6.38e-07	7.36e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—melanoma	6.36e-07	7.33e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—melanoma	6.3e-07	7.26e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—melanoma	6.29e-07	7.25e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—melanoma	6.24e-07	7.19e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.23e-07	7.18e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—melanoma	6.22e-07	7.17e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—melanoma	6.22e-07	7.17e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—melanoma	6.22e-07	7.17e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—melanoma	6.14e-07	7.08e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—melanoma	6.1e-07	7.03e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—melanoma	6.05e-07	6.97e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—melanoma	6.01e-07	6.93e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—melanoma	5.99e-07	6.91e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK3—melanoma	5.96e-07	6.87e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—melanoma	5.94e-07	6.85e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—melanoma	5.8e-07	6.68e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—melanoma	5.78e-07	6.67e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—melanoma	5.74e-07	6.62e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—melanoma	5.73e-07	6.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—melanoma	5.73e-07	6.6e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAPK1—melanoma	5.67e-07	6.54e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—melanoma	5.65e-07	6.52e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—melanoma	5.59e-07	6.45e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—melanoma	5.58e-07	6.43e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—melanoma	5.56e-07	6.41e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—melanoma	5.52e-07	6.36e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—melanoma	5.51e-07	6.35e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—melanoma	5.49e-07	6.33e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—melanoma	5.44e-07	6.27e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—melanoma	5.36e-07	6.18e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—melanoma	5.27e-07	6.08e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—melanoma	5.27e-07	6.07e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—melanoma	5.22e-07	6.02e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—melanoma	5.2e-07	6e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—melanoma	5.16e-07	5.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PRKCA—melanoma	5e-07	5.77e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—melanoma	4.99e-07	5.76e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—melanoma	4.96e-07	5.72e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—melanoma	4.95e-07	5.7e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—melanoma	4.92e-07	5.67e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—melanoma	4.87e-07	5.62e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—melanoma	4.83e-07	5.57e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—melanoma	4.81e-07	5.54e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—melanoma	4.76e-07	5.49e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—melanoma	4.59e-07	5.29e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—melanoma	4.55e-07	5.25e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—melanoma	4.55e-07	5.25e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—melanoma	4.55e-07	5.25e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—melanoma	4.51e-07	5.2e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—melanoma	4.49e-07	5.17e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—melanoma	4.36e-07	5.02e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—melanoma	4.31e-07	4.97e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—melanoma	4.21e-07	4.85e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—melanoma	4.02e-07	4.63e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—melanoma	3.97e-07	4.57e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—melanoma	3.94e-07	4.54e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—melanoma	3.93e-07	4.54e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—melanoma	3.92e-07	4.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—melanoma	3.78e-07	4.36e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—melanoma	3.72e-07	4.29e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—melanoma	3.44e-07	3.97e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—melanoma	3.4e-07	3.92e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—melanoma	3.39e-07	3.91e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—melanoma	3.22e-07	3.71e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—melanoma	3.04e-07	3.51e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—melanoma	3.04e-07	3.5e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—melanoma	3e-07	3.46e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—melanoma	2.97e-07	3.43e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—melanoma	2.97e-07	3.42e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—melanoma	2.8e-07	3.23e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—melanoma	2.78e-07	3.2e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—melanoma	2.77e-07	3.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—melanoma	2.59e-07	2.99e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—melanoma	2.49e-07	2.87e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—melanoma	2.43e-07	2.8e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—melanoma	2.29e-07	2.64e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—melanoma	2.27e-07	2.61e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—melanoma	1.83e-07	2.11e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—melanoma	1.5e-07	1.72e-06	CbGpPWpGaD
